AbCellera Biologics (ABCL)

• Market cap: $3.87B
• 1 day: 0.08%
• 5 days: -3.48%
• 1 month: -5.69%
• 3 months: 105.86%
• 6 months: 205.37%
• Year to date: 248.1%
• 1 year: 103.75%
• 5 years: -25.56%
• 10 years: -79.73%
• Sector: Healthcare
• Industry: Biotechnology

About: AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Employees: 562